Medicare
We must not attempt to solve our nation’s budget problems on the backs of health care providers and patients. After years of a once-in-a-lifetime global pandemic where hospitals and health systems treated more than 6 million COVID-19 patients while simultaneously dealing with near historic…
The editorial board of The Washington Post has published an opinion piece calling for payment cuts to hospitals and health systems as part of efforts to stabilize the Medicare program. The editorial calls for adopting so-called site-neutral payment policies, decreasing federal payments to teaching…
On March 15, the Medicare Payment Advisory Commission (MedPAC) released its annual report on the commission’s recommendations for Fiscal Year 2024 Medicare payment updates.
Earlier this month the Medicare Payment Advisory Commission (MedPAC) released its annual March report on the commission’s recommendations for Fiscal Year 2024 Medicare payment updates. Some recent media articles have lazily used the report to suggest that “hospitals’ financial situations are not…
The AHA strongly opposes site-neutral payment cuts, which would reduce access to critical health care services, especially in rural and other underserved communities.
The Centers for Medicare and Medicaid Services (CMS) March 15 announced 27 prescription drugs for which it will lower Part B beneficiary coinsurance, beginning April 1 through June 30, 2023, as required by the Inflation Reduction Act (IRA).
The Centers for Medicare and Medicaid Services (CMS) March 15 announced 27 prescription drugs for which it will lower Part B beneficiary coinsurance, beginning April 1 through June 30, 2023, as required by the Inflation Reduction Act (IRA). This is a table of those drugs.
This April through June under the Inflation Reduction Act, Medicare will reduce the coinsurance amount for 27 Part B prescription drugs from 20% to somewhere between 10% and 19.9%, depending on the drug, the Centers for Medicare & Medicaid Services announced today.
In comments submitted Saturday, AHA generally supports the Centers for Medicare & Medicaid Services’ initial guidance implementing inflation rebates for certain single source drugs and biosimilar biological products covered by Medicare Part B, but recommends changes to prevent incentivizing…
AHA comments on the Centers for Medicare & Medicaid Services’ initial guidance regarding certain Inflation Reduction Act requirements.